Clinical trials: Respiratory Infections, Acute
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
Acute Upper Respiratory Tract Infection, Influenza
Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers
this study evaluates the use of Kagocel for the prevention of acute respiratory viral infections (ARVI) and influenza during the epidemic rise in morbidity in Russia in the 2017-2018 season (epidemiology: number of cases during…
- Conditions
- Acute Upper Respiratory Tract Infection, Influenza, Respiratory Viral Infection
- Trial name
- NCT04611061
- Testing
- Kagocel, No one
- Where
- Russia
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Nearmedic Plus LLC
Common Cold, Infections, Upper Respiratory Tract
Acute Cough Study In Children
15 mg dextromethorphan hydrobromide will be better than placebo with respect to reducing the number of coughs over 6 hours and reducing the subjective severity of cough over 6 hours.
- Trial name
- NCT01257542
- Testing
- Dextromethorphan
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Acute Pharyngitis, Sore Throat
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
The study's purpose is to demonstrate the onset of action, i.e., time to meaningful pain relief in patients with pharyngitis, of flurbiprofen 8.75 mg lozenge using the Double-Stopwatch Method (DSW).
- Trial name
- NCT01986361
- Testing
- flurbiprofen
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Reckitt Benckiser LLC
COVID-19 Pneumonia, Bromelains Adverse Reaction
Nebulised BromAc in Healthy Volunteers
COVID-19 is a disease that has multiple facets including an inflammatory storm, it promotes blood clotting and causes kidney damage, mucinous secretions in the lung are of great importance to outcome.
- Conditions
- COVID-19 Pneumonia, Bromelains Adverse Reaction, Acetylcysteine Adverse Reaction, Mucus; Plug
- Trial name
- NCT05220605
- Testing
- BromAc
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mucpharm Pty Ltd
Common Cold, Acute Respiratory Infection
Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infections, and to determine the dosing regimen of XC8…
- Conditions
- Common Cold, Acute Respiratory Infection, Influenza, Human
- Trial name
- NCT05269329
- Testing
- XC8, film-coated tablets, 20 mg/day, XC8, film-coated tablets, 40 mg/day, XC8, film-coated tablets, 80 mg/day
- Where
- 9 sites in Russia
- Volunteers
- 160 people
- Sponsor
- Valenta Pharm JSC
Influenza
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
This is a randomized clinical trial designed to evaluate the safety/efficacy of two dosing regimens of oral nitazoxanide compared to placebo in the treatment of acute uncomplicated influenza in adults and adolescents.
- Trial name
- NCT01227421
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 624 people
- Sponsor
- Romark Laboratories L.C.
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.
Long COVID
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID.
- Trial name
- IMPACT-LC (NCT06974084)
- Testing
- Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- HealthBio, Inc.
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Respiratory Tract Infection
Effects of a Supplement on Acute Respiratory Infections
The purpose of this study is to determine whether the consumption of a nutritional supplement with micronutrients and herbal extracts has an effect on the incidence of acute respiratory infections in susceptible adults.
- Trial name
- NCT02210156
- Testing
- Omniplus Supreme
- Where
- Mexico
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Omnilife Manufactura, SA de CV
ACUTE SINUSITIS
Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis
To evaluate the efficacy and safety of Cyclamen europaeum extract 10 % (v/v) compared to placebo in subjects with acute sinusitis
- Trial name
- NCT00552773
- Testing
- Cyclamen Europaeum
- Where
- 25 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dey
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19 (based on World Health Organization [WHO]…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05085574
- Testing
- Famotidine, Celecoxib
- Sponsor
- Leidos Life Sciences
COVID-19 Pneumonia, Acute Respiratory Distress Syndrome
Respiratory COVID-19: A Randomized, Sham-Controlled Study
A study of intubated critically ill patients infected with SARS-COV-2 to evaluate the safety and treatment effects of ultraviolet-A (UVA) light administered by a novel device via endotracheal tube in a first-in-human study.
- Conditions
- COVID-19 Pneumonia, Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Respiratory Infection
- Trial name
- NCT05166915
- Testing
- UVA Light Emitting Catheter
- Where
- 2 sites in Spain
- Sponsor
- Aytu BioPharma, Inc.
Long Covid, Depression
Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID
This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression.
- Conditions
- Long Covid, Depression, Anxiety
- Trial name
- NCT07714889
- Testing
- Rauha® Digital Therapeutic Platform (Toivoa-004)
- Sponsor
- Toivoa Inc
Acute Lung Injury, Acute Kidney Injury
Safety and Efficacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration Therapy
Objective of the study is to assess the safety and efficacy of CO2 removal by the multiECCO2R (CO2 Removal System) on the multiFiltrate/multiFiltrate Pro in veno-venous extracorporeal circulation during continuous renal…
- Conditions
- Acute Lung Injury, Acute Kidney Injury, Hypercapnia, Covid19
- Trial name
- multiECCO2R (NCT04871893)
- Testing
- multiECCO2R blood-gas exchanger
- Where
- 6 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Influenza, Respiratory Viral Infection
A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
The main purpose of the study was to evaluate the effectiveness of XC221, tablets, at a dose of 200 mg/day compared to placebo in patients with uncomplicated influenza or other acute respiratory viral infections (ARIs).
- Trial name
- NCT05544916
- Testing
- XC221
- Where
- 13 sites in Russia
- Volunteers
- 260 people
- Sponsor
- Valenta Pharm JSC
Influenza, Acute Respiratory Viral Infection
Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
The objective of this study is to investigate the efficacy, safety, and tolerability of investigational product Ingavirin forte capsules (Valenta Pharm JSC) administered at different doses compared with medicinal product…
- Trial name
- NCT07420985
- Testing
- Ingavirin Forte, 90 mg + 5 mg, Capsules, Ingavirin Forte, 90 mg + 10 mg, Capsules, Ingavirin Forte, 90 mg + 20 mg, Capsules
- Where
- 11 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Valenta Pharm JSC